medigraphic.com

2018, Número 1

<< Anterior Siguiente >>

Rev Hosp Jua Mex 2018; 85 (1)


Clostridium difficile: cambio de paradigmas en la epidemiología hospitalaria y el control de infecciones

Sosa-Hernández O, Alarcón-Hernández GP, Matías-Téllez B, Cureño-Díaz MA

Idioma: Español
Referencias bibliográficas: 40
Paginas: 39-44
Archivo PDF: 173.50 Kb.


RESUMEN

En los últimos años la infección por Clostridium difficile se ha presentado como un gran desafío en materia de control de infecciones dentro de las instituciones de salud del mundo, debido a que es uno de los principales agentes etiológicos de las infecciones asociadas a la atención de la salud que causa una importante repercusión en el paciente y en la institución. Nuestro país no es la excepción, ya que en diversos hospitales se han presentado brotes de Clostridium difficile. En especial se ha descrito la presencia de la cepa BI/NAP1/027, una cepa altamente virulenta que ha ocasionado tasas de incidencia similares a las reportadas en Europa y Estados Unidos. La presencia de Clostridium difficile en los hospitales representa un gran reto para los líderes en el control de infecciones, pues rompe con los paradigmas en la epidemiología hospitalaria.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 373(3): 287-8.

  2. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8(1): 17-26.

  3. Camacho-Ortiz A, López-Barrera D, Hernández-García R, Galván-De Los Santos AM, Flores-Treviño SM, Llaca-Díaz JM, et al. First report of Clostridium difficile NAP1/027 in a Mexican hospital. PLoS One 2015; 10(4): e0122627.

  4. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365(18): 1693-703.

  5. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41(9): 1254-60.

  6. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10(3): 225-33.

  7. Acosta-Gnass SA. Pacientes infectados con Clostridium difficile. Manual de control de infecciones y epidemiología hospitalaria. Organización Panamericana de la Salud; 2011. p. 174-6.

  8. Hall IC, O’Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935; 49(2): 390-402.

  9. Portillo-López MI, Castellanos-Urdaibay MA, Cortés-Nava E, Chiprut R. Clostridium difficile infection. Gac Med Mex 2002; 138(1): 57-66.

  10. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353(23): 2433-41.

  11. Soler P, Nogareda F, Cano R. Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005. Infect Control Hosp Epidemiol 2008; 29(9): 887-9.

  12. Pérez M, Hurtado AI, Couto I, Gutiérrez JM, Seoane L, Suárez JM, et al. Abordaje multidisciplinario de la infección por Clostridium difficile. Rev Chil Infectol 2013; 30(2): 165-85.

  13. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16(8): 459-77.

  14. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18(2): 247-63.

  15. Rocha MF, Sidrim JJ, Lima AA. Clostridium difficile as an inducer of inflammatory diarrhea. Rev Soc Bras Med Trop 1999; 32(1): 47-52.

  16. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995; 95(5): 2004-11.

  17. van der Waaij D. The ecology of the human intestine and its consequences for overgrowth by pathogens such as Clostridium difficile. Annu Rev Microbiol 1989; 43: 69-87.

  18. Burdon DW, George RH, Mogg GA, Arabi Y, Thompson H, Johnson M, et al. Faecal toxin and severity of antibiotic-associated pseudomembranous colitis. J Clin Pathol 1981; 34(5): 548-51.

  19. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357(9251): 189-93.

  20. O’Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136(6): 1913-24.

  21. Morfin-Otero R, Garza-Gonzalez E, Aguirre-Diaz SA, Escobedo-Sanchez R, Esparza-Ahumada S, Perez-Gomez HR, et al. Clostridium difficile outbreak caused by NAP1/BI/027 strain and non-027 strains in a Mexican hospital. Braz J Infect Dis 2016; 20(1): 8-13.

  22. Dávila LP, Garza-González E, Rodríguez-Zulueta P, Morfín-Otero R, Rodríguez-Noriega E, Vilar-Compte D, et al. Increasing rates of Clostridium difficile infection in Mexican hospitals. Braz J Infect Dis 2017; 21(5): 530-4.

  23. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007; 35(10 Suppl 2): S165-93.

  24. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35(10 Suppl 2): S65-164.

  25. Hohenberger H. The OR environment--hand hygiene, cleaning, and Clostridium difficile. AORN J 2015; 102(6): 584-7.

  26. McGoldrick M. Hand hygiene and Clostridium difficile infections. Home Healthc Now 2015; 33(6): 340-1.

  27. Doan L, Forrest H, Fakis A, Craig J, Claxton L, Khare M. Clinical and cost effectiveness of eight disinfection methods for terminal disinfection of hospital isolation rooms contaminated with Clostridium difficile 027. J Hosp Infect 2012; 82(2): 114-21.

  28. Rutala WA, Weber DJ, Committee HICPAC. Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008. Last update: February 15, 2017.

  29. Weber DJ, Kanamori H, Rutala WA. ‘No touch’ technologies for environmental decontamination: focus on ultraviolet devices and hydrogen peroxide systems. Curr Opin Infect Dis 2016; 29(4): 424-31.

  30. McCord J, Prewitt M, Dyakova E, Mookerjee S, Otter JA. Reduction in Clostridium difficile infection associated with the introduction of hydrogen peroxide vapour automated room disinfection. J Hosp Infect 2016; 94(2): 185-7.

  31. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40(1): 1-15.

  32. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 2010; 51(1): 2-7.

  33. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.

  34. Patton A, Davey P, Harbarth S, Nathwani D, Sneddon J, Marwick CA. Impact of antimicrobial stewardship interventions on Clostridium difficile infection and clinical outcomes: segmented regression analyses. J Antimicrob Chemother 2018; 73(2): 517-26.

  35. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108(4): 478-98; quiz 499.

  36. Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014; 35(6): 628-45.

  37. Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tüll P, Gastmeier P, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 Suppl 5: 2-20.

  38. Pérez M, Hurtado AI, Couto I, Gutiérrez JM, Seoane L, Suárez JM, et al. Abordaje multidisciplinario de la infección por Clostridium difficile. Rev Chil Infectol 2013; 30(2): 165-85.

  39. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170(9): 784-90.

  40. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S12-8.




2020     |     www.medigraphic.com